|1.||Hong, Ki Whan: 22 articles (10/2015 - 03/2002)|
|2.||Kim, Chi Dae: 17 articles (10/2015 - 09/2003)|
|3.||Lee, Won Suk: 17 articles (10/2015 - 09/2003)|
|4.||Park, So Youn: 16 articles (10/2015 - 03/2004)|
|5.||Shin, Hwa Kyoung: 13 articles (10/2014 - 03/2002)|
|6.||Lee, Jeong Hyun: 13 articles (08/2010 - 03/2002)|
|7.||Kim, Jong S: 12 articles (05/2015 - 04/2005)|
|8.||Uchiyama, Shinichiro: 12 articles (03/2015 - 11/2003)|
|9.||Rhim, Byung Yong: 11 articles (02/2014 - 09/2003)|
|10.||Kwon, Sun U: 10 articles (10/2015 - 04/2005)|
08/01/2015 - "More randomized controlled trials in non-East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke."
12/15/2005 - "In the Cilostazol Stroke Prevention Study, a randomized double-blind, placebo-controlled trial involving more than 1000 Japanese patients, cilostazol was found to reduce the risk of secondary stroke by 41.7% compared with placebo, a statistically significant reduction (P = 0.015). "
01/01/2008 - "Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. "
03/01/2015 - "Studies in Asia have shown that cilostazol is effective in the secondary prevention of stroke. "
07/01/2015 - "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke. "
01/01/2001 - "Clinical trials demonstrating a significant improvement in walking distances with cilostazol therapy suggest that it will be an important tool in improving symptoms and quality of life in patients with intermittent claudication."
11/01/2006 - "Cilostazol is a potent selective inhibitor of phosphodiesterase-3 of proven efficacy in intermittent claudication. "
01/01/2003 - "In six of eight well designed clinical trials, cilostazol was significantly more effective than placebo in increasing walking distances and improving the quality of life of patients with moderate to severe intermittent claudication. "
01/01/2003 - ", double-blind, placebo-controlled 12- to 24-week trials in >2000 patients with moderate to severe intermittent claudication demonstrated that cilostazol generally significantly increased walking distances and improved quality of life compared with placebo. "
08/10/2013 - "Cilostazol has been found to be effective for the treatment of intermittent claudication (IC). "
04/01/2010 - "The purpose of this study was to investigate the efficacy of cilostazol for prevention of thrombosis in microsurgical anastomosis. "
01/01/2001 - "Small, nonblind studies suggest that cilostazol may prove useful in preventing thrombosis and restenosis following percutaneous coronary interventions, although these remain unlabeled uses. "
05/01/2012 - "Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. "
01/01/2012 - "Also in an arteriovenous shunt thrombosis model, K-134 showed an antithrombotic effect greater than cilostazol. "
06/01/2011 - "We evaluate the anti-platelet and anti-thrombotic effects of cilostazol using Multiplate® and PFA-100® in vitro and ex vivo with freshly isolated rat whole blood and in vivo venous and arterial thrombosis models in the same species, in an effort to assess the sensitivity of the whole blood aggregometer assays without potential issues of species differences. "
04/01/2015 - "Administration of cilostazol resulted in a significant reduction in motor dysfunction when compared with the ischemia-reperfusion group (p<0.001). "
01/01/2012 - "Cilostazol significantly reduced mortality rate and improved motor function at 7 days post-ischemia/reperfusion. "
01/01/2006 - "Under treatment with cilostazol (10 mg/kg intravenously or 30 mg/kg orally), a significant reduction in cerebral infarct area was evident in rats subjected to ischemia/reperfusion. "
12/05/2013 - "Cilostazol is effective for the treatment of peripheral ischemia. "
08/01/2012 - "Cilostazol at a dose of 30 mg/kg twice a day promoted improvement in gait performance in rats submitted to chronic hindlimb ischemia. "
12/01/2000 - "More recently, cilostazol was shown to be effective in a clinical prevention study on recurrence of cerebral infarction, and has been applied to the approval of the indication in Japan."
10/01/2012 - "Cilostazol has been shown to be effective for prevention and treatment of cerebral infarction. "
01/01/2011 - "Several reports have indicated that cilostazol is effective in the prevention of recurrence after cerebral infarction. "
03/01/2001 - "Cilostazol, an inhibitor of platelet aggregation, was thus concluded to be effective in improving cerebral blood flow, cerebral function, and serum lipid levels in patients in the chronic stage of cerebral infarction."
07/01/2000 - "Long-term administration of cilostazol was effective and safe in the secondary prevention of cerebral infarction. "
|1.||Aspirin (Acetylsalicylic Acid)
|2.||Type 3 Cyclic Nucleotide Phosphodiesterases
|4.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)